China Resources Xinlong Pharmaceutical Co., Ltd. is a large private pharmaceutical logistics enterprise funded by Mr. Yang Sizhi and approved by the State Administration for Industry and Commerce. The company was established in June 1999. The registered capital is/kloc-0.50 billion yuan, the total assets are 3.2 billion yuan, and there are 3,000 employees. In order to support the local economic and social development, the group headquarters moved from Beijing to Wuhan in May 2008. The Group has 22 wholly-owned subsidiaries in Beijing, Tianjin, Hubei, Guangzhou, Zhengzhou and Taiyuan. The core business of the company is the wholesale, sales chain and e-commerce of drugs, health products, Chinese herbal pieces, Chinese herbal pieces and medical devices. Since 2000, the company's sales performance has been rising year after year, reaching 200 million yuan, 350 million yuan, 650 million yuan, 830 million yuan, 65.438+0.5 billion yuan, 2 billion yuan, 3.8 billion yuan, 5.5 billion yuan, 6 billion yuan and 6.5 billion yuan respectively. The average annual sales increased by more than 20%. Since the establishment of the company. In 20 10, the sales revenue of the group was 7 billion yuan, the local sales revenue of Hubei was 2 billion yuan, and the profit and tax 1 100 million yuan. On 20 1 1 year, the company's predecessor, Xinlong Pharmaceutical Group, achieved strategic cooperation with China Resources Pharmaceutical Commercial Group, and * * * established China Resources Xinlong Pharmaceutical Co., Ltd., which has now become a pharmaceutical commercial platform enterprise of China Resources Pharmaceutical in Hubei. For seven consecutive years, the company has been rated as one of the top 500 private enterprises in China (2 12), one of the top 100 enterprises in Wuhan (19), an essential drug distribution unit in Hubei Province (awarded by the provincial medical reform bidding office), a drug reserve base in Wuhan City (awarded by the US Food and Drug Administration), "an honest enterprise for ensuring the quality of the pharmaceutical market in Hubei Province" and "a contract-abiding enterprise in Wuhan City".
The company has a certain medical supplies reserve base. The existing warehouse area of Hubei headquarters of the Group is 20,000 square meters, the drug inventory is 200 million yuan, and the drug inventory is 200,000 boxes. There is a cold storage of nearly 200 square meters, which meets the GSP quality management professional library, such as odor library, cold taste library, normal temperature library, special library for second-class psychotropic drugs, etc. More than 5,000 key pharmaceutical enterprises in China have supply cooperation relations with group companies, with more than 8,000 sales customers. All kinds of commonly used drugs and rare drugs are available all year round. The company's management automation level is high, all the reserved drugs are managed by computer, and the group and its subsidiaries realize online electronic business links and centralized data processing. The company is the first pharmaceutical commercial logistics enterprise in Wuhan that has passed GSP certification. For a long time, Hubei Company has been responsible for drug distribution in hospitals, other medical institutions and pharmaceutical commercial enterprises in the province.
With the development of the company and the popularization of medical insurance in our province, there are new requirements for the modernization of medical circulation. At present, the company has built a modern medicine logistics reserve and distribution base of China Resources Xinlong Co., Ltd. in Wuhan Economic and Technological Development Zone, with a total investment of more than 400 million yuan and a total construction area of more than 60,000 square meters. The modernization of the project and the scale of logistics and distribution will become the largest and most advanced medical logistics reserve and distribution center in the six central and southern provinces.